Viking Therapeutics, Inc. Basic Shares Outstanding (Weighted Average)
Viking Therapeutics, Inc. (VKTX) reported Basic Shares Outstanding (Weighted Average) of 116.26 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-07-29
- Viking Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 116.26M shares, a 3.68% increase year-over-year.
- Viking Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 115.57M shares, a 3.12% increase year-over-year.
- Viking Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 114.02M shares, a 2.39% increase year-over-year.
- Viking Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 112.32M shares, a 1.27% increase year-over-year.
- Viking Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 112.67M shares, a 3.33% increase from fiscal 2024.
- Viking Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 109.04M shares, a 15.57% increase from fiscal 2023.
- Viking Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 94.35M shares, a 22.79% increase from fiscal 2022.
- Viking Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 76.83M shares, a 0.47% decline from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 116.26M shares 10-Q · filed 2026-07-29 | 115.92M shares 10-Q · filed 2026-07-29 | 115.28M shares derived: average of 3 quarters · filed 2026-07-29 | 114.54M shares derived: average of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | 115.57M shares 10-Q · filed 2026-04-30 | 114.79M shares derived: average of 2 quarters · filed 2026-04-30 | 113.97M shares derived: average of 3 quarters · filed 2026-04-30 | 113.51M shares derived: average of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | 114.02M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | 113.17M shares derived: average of 2 quarters · filed 2026-02-11 | 112.82M shares derived: average of 3 quarters · filed 2026-07-29 | 112.67M shares 10-K · filed 2026-02-11 |
| 2025-09-30 | 112.32M shares 10-Q · filed 2025-10-23 | 112.23M shares derived: average of 2 quarters · filed 2026-07-29 | 112.22M shares 10-Q · filed 2025-10-23 | 111.97M shares derived: average of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | 112.13M shares 10-Q · filed 2026-07-29 | 112.10M shares 10-Q · filed 2026-07-29 | 111.85M shares derived: average of 3 quarters · filed 2026-07-29 | 111.62M shares derived: average of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | 112.07M shares 10-Q · filed 2026-04-30 | 111.72M shares derived: average of 2 quarters · filed 2026-04-30 | 111.45M shares derived: average of 3 quarters · filed 2026-04-30 | 111.18M shares derived: average of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | 111.36M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | 111.14M shares derived: average of 2 quarters · filed 2026-02-11 | 110.89M shares derived: average of 3 quarters · filed 2026-02-11 | 109.04M shares 10-K · filed 2026-02-11 |
| 2024-09-30 | 110.91M shares 10-Q · filed 2025-10-23 | 110.65M shares derived: average of 2 quarters · filed 2025-10-23 | 108.26M shares 10-Q · filed 2025-10-23 | 106.18M shares derived: average of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | 110.39M shares 10-Q · filed 2025-07-23 | 106.92M shares 10-Q · filed 2025-07-23 | 104.60M shares derived: average of 3 quarters · filed 2026-02-11 | 103.41M shares derived: average of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | 103.46M shares 10-Q · filed 2025-04-24 | 101.70M shares derived: average of 2 quarters · filed 2026-02-11 | 101.08M shares derived: average of 3 quarters · filed 2026-02-11 | 100.56M shares derived: average of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | 99.94M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | 99.90M shares derived: average of 2 quarters · filed 2026-02-11 | 99.60M shares derived: average of 3 quarters · filed 2026-02-11 | 94.35M shares 10-K · filed 2026-02-11 |
| 2023-09-30 | 99.85M shares 10-Q · filed 2024-10-23 | 99.43M shares derived: average of 2 quarters · filed 2024-10-23 | 92.48M shares 10-Q · filed 2024-10-23 | 88.45M shares derived: average of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | 99.01M shares 10-Q · filed 2024-07-24 | 88.74M shares 10-Q · filed 2024-07-24 | 84.65M shares derived: average of 3 quarters · filed 2025-02-26 | 82.61M shares derived: average of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | 78.35M shares 10-Q · filed 2024-04-25 | 77.47M shares derived: average of 2 quarters · filed 2025-02-26 | 77.15M shares derived: average of 3 quarters · filed 2025-02-26 | 77.07M shares derived: average of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | 76.58M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | 76.54M shares derived: average of 2 quarters · filed 2025-02-26 | 76.64M shares derived: average of 3 quarters · filed 2025-02-26 | 76.83M shares 10-K · filed 2025-02-26 |
| 2022-09-30 | 76.51M shares 10-Q · filed 2023-10-25 | 76.67M shares derived: average of 2 quarters · filed 2023-10-25 | 76.92M shares 10-Q · filed 2023-10-25 | 77.21M shares derived: average of 4 quarters · filed 2024-02-07 |
| 2022-06-30 | 76.84M shares 10-Q · filed 2023-07-26 | 77.13M shares 10-Q · filed 2023-07-26 | 77.44M shares derived: average of 3 quarters · filed 2024-02-07 | 77.58M shares derived: average of 4 quarters · filed 2024-02-07 |
| 2022-03-31 | 77.41M shares 10-Q · filed 2023-04-26 | 77.74M shares derived: average of 2 quarters · filed 2024-02-07 | 77.83M shares derived: average of 3 quarters · filed 2024-02-07 | 77.85M shares derived: average of 4 quarters · filed 2024-02-07 |
| 2021-12-31 | 78.07M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-07 | 78.04M shares derived: average of 2 quarters · filed 2024-02-07 | 77.99M shares derived: average of 3 quarters · filed 2024-02-07 | 77.20M shares 10-K · filed 2024-02-07 |
| 2021-09-30 | 78.01M shares 10-Q · filed 2022-10-26 | 77.95M shares derived: average of 2 quarters · filed 2022-10-26 | 76.91M shares 10-Q · filed 2022-10-26 | |
| 2021-06-30 | 77.90M shares 10-Q · filed 2022-07-27 | 76.35M shares 10-Q · filed 2022-07-27 | ||
| 2019-03-31 | 71.76M shares 10-Q · filed 2019-05-02 | |||
| 2018-09-30 | 61.23M shares 10-Q · filed 2018-11-07 | 57.00M shares derived: average of 2 quarters · filed 2018-11-07 | 52.94M shares 10-Q · filed 2018-11-07 | |
| 2018-06-30 | 52.77M shares 10-Q · filed 2018-08-09 | 48.73M shares 10-Q · filed 2018-08-09 | ||
| 2018-03-31 | 44.65M shares 10-Q · filed 2019-05-02 | |||
| 2017-09-30 | 27.47M shares 10-Q · filed 2018-11-07 | 25.79M shares derived: average of 2 quarters · filed 2018-11-07 | 24.67M shares 10-Q · filed 2018-11-07 | |
| 2017-06-30 | 24.12M shares 10-Q · filed 2018-08-09 | 23.24M shares 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | 22.35M shares 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |